Key Points
- Director Robert Bessler sold 12,371 shares on Dec. 15 at $7.00 for $86,597 (having also sold 79,630 shares on Dec. 12), reducing his stake by 0.89% to 1,375,989 shares valued at about $9.63M.
- LFST opened at $6.88 and trades in a 52-week range of $3.74–$8.30 with a market cap of $2.68B and a negative P/E (-229.33); the company recently beat quarterly EPS and revenue estimates but still reported a slight negative net margin.
- 85.5% institutional ownership with Vanguard, UBS and others increasing positions, and analysts show mixed views but a consensus "Moderate Buy" rating with an average price target of $8.83.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 12,371 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $7.00, for a total value of $86,597.00. Following the completion of the sale, the director owned 1,375,989 shares of the company's stock, valued at $9,631,923. This represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Robert Bessler also recently made the following trade(s):
- On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $558,206.30.
LifeStance Health Group Stock Down 0.6%
Shares of LFST stock opened at $6.88 on Wednesday. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The stock has a fifty day moving average price of $5.90 and a 200 day moving average price of $5.34. The stock has a market cap of $2.68 billion, a P/E ratio of -229.33 and a beta of 1.13.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.03. The company had revenue of $363.81 million during the quarter, compared to analysts' expectations of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business's revenue was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.02) EPS. Analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.
Institutional Investors Weigh In On LifeStance Health Group
A number of large investors have recently bought and sold shares of the business. AustralianSuper Pty Ltd bought a new stake in shares of LifeStance Health Group during the third quarter worth $17,056,000. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company's stock valued at $80,374,000 after buying an additional 2,383,728 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock worth $26,363,000 after buying an additional 1,839,465 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company's stock worth $45,998,000 after acquiring an additional 1,790,694 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new stake in LifeStance Health Group in the 3rd quarter valued at about $8,250,000. 85.50% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have commented on the stock. Barclays started coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an "overweight" rating and a $8.00 price target for the company. BMO Capital Markets started coverage on LifeStance Health Group in a report on Thursday, November 13th. They issued an "outperform" rating and a $8.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of LifeStance Health Group in a research report on Monday. Wall Street Zen cut LifeStance Health Group from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Finally, Zacks Research cut LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.
Get Our Latest Report on LFST
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
